Article

Pharmaceutical Executive

Tufts CSDD Releases Findings from Diabetes Study

Author(s):

Applied Clinical Trials Editorial Staff

September 26, 2016

According to results of a new study by the Tufts Center for the Study of Drug Development, the development process for new diabetes and non-diabetes endocrine drugs is riskier compared to all drug development. The study examined the development pathways and characteristics of 27 diabetes and 34 non-diabetes endocrine drugs.

Read the full release here

Newsletter

Lead with insight with the Pharmaceutical Executive newsletter, featuring strategic analysis, leadership trends, and market intelligence for biopharma decision-makers.

Subscribe Now!
Related Videos
Gen Li
Gen Li
Ted Sweetser
Ted Sweetser
Ted Sweetser
Related Content
Gaugarin Oliver
August 2nd 2025

Navigating Uncertainty with AI: Building Trust in the Way Forward

Gaugarin Oliver
Despite surging GenAI adoption in pharma and the FDA’s recent embrace of the technology, a trust gap remains with GenAI implementations. The story describes four essentials that improve trust in GenAI so that pharma and biotech teams can better navigate the present time of uncertainty.
Revolutionizing Patient Adherence: Leveraging AI for Personalized Engagement
August 2nd 2025

Revolutionizing Patient Adherence: Leveraging AI for Personalized Engagement

Miranda Schmalfuhs
Bill Grambley, CEO of AllazoHealth, delves into the potential of AI to revolutionize patient engagement and adherence.
Stock.adobe.com
August 2nd 2025

Can AI Accelerate Clinical Review at FDA?

PharmExec Staff
With reports that FDA’s AI Elsa is “confidently hallucinating” studies that don’t exist, the use of AI to streamline drug review and speed up approval is not here yet.
Snyder and Capan
August 2nd 2025

Accelerating AI: Q&A with Faruk Capan and Scott Snyder

Pharmaceutical Executive
The EVERSANA team discusses its new technology center that has a goal of pharmatizing AI.
Stock.adobe.com
August 2nd 2025

TrueMed and Alliance Pharmaceuticals Ltd Form Partnership to Create AI-Powered Counterfeit Solutions

Nicholas Jacobus
Alliance Pharmaceuticals plans to use the new to attack counterfeiters rather than just defend against them.
Kevin Riley
August 2nd 2025

AI Can’t Lead. Healthcare Needs Leaders

Kevin Riley
It’s the caliber of leadership that brings teams together, demands accountability, and drives purposeful, decisive action.